$SSY
SUNLINK HEALTH SYSTEMS INC Stock $ssy

$ssy Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000095017024110311 Filed on September 30, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2024
Revenue	$7.923M	$7.913M	$32.44M
YoY Change	-7.39%	-27.98%	-32.34%
Cost Of Revenue		$4.382M	$18.25M
YoY Change		-11.1%	-1.87%
Gross Profit		$3.531M	$14.19M
YoY Change		-41.71%	-51.74%
Gross Profit Margin		44.62%	43.73%
Selling, General & Admin		$3.058M	$12.21M
YoY Change		-50.61%	-51.54%
% of Gross Profit		86.6%	86.07%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$413.0K	$1.373M
YoY Change		-30.7%	-22.21%
% of Gross Profit		11.7%	9.68%
Operating Expenses		$4.206M	$16.60M
YoY Change		-47.64%	-47.64%
Operating Profit	-$1.194M	-$675.0K	-$2.411M
YoY Change	165.33%	-65.82%	3.83%
Interest Expense		$23.00K	$93.00K
YoY Change		-68.92%	-7.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$442.0K	-$652.0K	-$2.316M
YoY Change	3.76%	-54.6%	39.35%
Income Tax	$0.00	$0.00	-$5.000K
% Of Pretax Income
Net Earnings	-$549.0K	$4.288M	-$1.527M
YoY Change	-59.15%	-400.7%	-14.93%
Net Earnings / Revenue	-6.93%	54.19%	-4.71%
Basic Earnings Per Share	-$0.08		-$0.22
Diluted Earnings Per Share	-$0.08	$0.60	-$0.22
COMMON SHARES
Basic Shares Outstanding	7.041M	7.041M	7.038M
Diluted Shares Outstanding	7.041M		7.038M

Balance Sheet

Concept	2024 Q3	2024 Q2	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments		$7.170M	$7.170M
YoY Change		59.83%	59.33%
Cash & Equivalents	$7.529M	$7.170M	$7.170M
Short-Term Investments
Other Short-Term Assets		$3.570M	$3.570M
YoY Change		100.22%	98.33%
Inventory	$1.547M	$1.553M	$1.553M
Prepaid Expenses
Receivables		$3.371M	$3.371M
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$15.62M	$15.66M	$15.66M
YoY Change	-5.54%	27.62%	27.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.316M	$2.809M	$3.325M
YoY Change	-19.89%	-66.08%	-64.25%
Goodwill
YoY Change
Intangibles	$1.180M	$1.180M
YoY Change	0.0%	0.0%
Long-Term Investments
YoY Change
Other Assets	$44.00K	$443.0K	$443.0K
YoY Change	-88.69%	-9.41%	-11.4%
Total Long-Term Assets	$4.013M	$4.948M	$4.948M
YoY Change	-22.71%	-55.0%	-55.02%
TOTAL ASSETS
Total Short-Term Assets	$15.62M	$15.66M	$15.66M
Total Long-Term Assets	$4.013M	$4.948M	$4.948M
Total Assets	$19.63M	$20.61M	$20.61M
YoY Change	-9.64%	-11.42%	-11.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.338M	$1.905M	$1.905M
YoY Change	-1.55%	3.03%	5.83%
Accrued Expenses		$2.308M	$2.308M
YoY Change		-22.71%	-23.07%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.851M	$4.213M	$4.213M
YoY Change	-22.87%	-13.47%	-14.02%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$69.00K	$180.0K	$426.0K
YoY Change	-38.94%	76.47%	-52.67%
Total Long-Term Liabilities	$354.0K	$426.0K	$426.0K
YoY Change	-45.62%	-56.66%	-52.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.851M	$4.213M	$4.213M
Total Long-Term Liabilities	$354.0K	$426.0K	$426.0K
Total Liabilities	$4.205M	$4.639M	$4.639M
YoY Change	-25.5%	-20.73%	-21.37%
SHAREHOLDERS EQUITY
Retained Earnings	$929.0K	$1.478M
YoY Change	-44.07%	-50.82%
Common Stock	$14.27M	$14.27M
YoY Change	0.0%	0.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$15.97M	$15.97M
YoY Change
Total Liabilities & Shareholders Equity	$19.63M	$20.61M	$20.61M
YoY Change	-9.64%	-11.42%	-11.54%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2024
OPERATING ACTIVITIES
Net Income	-$549.0K	$4.288M	-$1.527M
YoY Change	-59.15%	-400.7%	-14.93%
Depreciation, Depletion And Amortization		$413.0K	$1.373M
YoY Change		-30.7%	-22.21%
Cash From Operating Activities	-$915.0K	-$386.0K	-$2.978M
YoY Change	-19.53%	-8.31%	451.48%
INVESTING ACTIVITIES
Capital Expenditures	$191.0K	$385.0K	$1.467M
YoY Change	-59.87%	-18.95%	-26.65%
Acquisitions
YoY Change
Other Investing Activities		$6.730M	$7.235M
YoY Change		61081.82%	3188.64%
Cash From Investing Activities	$1.274M	$6.345M	$5.670M
YoY Change	-343.13%	-1467.46%	-419.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$0.00		$14.00K
YoY Change	-100.0%		-65.0%
Cash From Financing Activities	0.000	0.000	-8.000K
YoY Change	-100.0%	-100.0%	-200.0%
NET CHANGE
Cash From Operating Activities	-915.0K	-386.0K	-2.978M
Cash From Investing Activities	1.274M	6.345M	5.670M
Cash From Financing Activities	0.000	0.000	-8.000K
Net Change In Cash	359.0K	5.959M	2.684M
YoY Change	-121.55%	-765.07%	-216.29%
FREE CASH FLOW
Cash From Operating Activities	-$915.0K	-$386.0K	-$2.978M
Capital Expenditures	$191.0K	$385.0K	$1.467M
Free Cash Flow	-$1.106M	-$771.0K	-$4.445M
YoY Change	-31.43%	-13.95%	75.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0000096793
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2024Q2	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent
CY2023Q2	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent
CY2024Q2	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent
CY2024	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost Credit Excluding Service Cost Statement Of Income Or Comprehensive Income Extensible List DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList	http://fasb.org/us-gaap/2024#InterestIncomeExpenseNet
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	1-12607
CY2024	dei	Entity Registrant Name EntityRegistrantName	SunLink Health Systems, Inc.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	GA
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	31-0621189
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	900 Circle 75 Parkway
CY2024	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 690
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Atlanta
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30339
CY2024	dei	City Area Code CityAreaCode	770
CY2024	dei	Local Phone Number LocalPhoneNumber	933-7000
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7040603
CY2023Q4	dei	Entity Public Float EntityPublicFloat	5065824
CY2024	dei	Auditor Name AuditorName	Cherry Bekaert, LLP
CY2024	dei	Auditor Location AuditorLocation	Atlanta, Georgia
CY2024	dei	Auditor Firm AuditorFirmId	677
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7170000
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4486000
CY2024Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	3371000
CY2023Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	2592000
CY2024Q2	us-gaap	Inventory Net InventoryNet	1553000
CY2023Q2	us-gaap	Inventory Net InventoryNet	1628000
CY2024Q2	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	1959000
CY2023Q2	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	1920000
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1611000
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1648000
CY2024Q2	us-gaap	Assets Current AssetsCurrent	15664000
CY2023Q2	us-gaap	Assets Current AssetsCurrent	12274000
CY2024Q2	us-gaap	Land Land	371000
CY2023Q2	us-gaap	Land Land	371000
CY2024Q2	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	520000
CY2023Q2	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	510000
CY2024Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	11792000
CY2023Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	10378000
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12683000
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11259000
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9874000
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8542000
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2809000
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2717000
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1180000
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1180000
CY2024Q2	ssy	Noncurrent Asset Held For Sale NoncurrentAssetHeldForSale	0
CY2023Q2	ssy	Noncurrent Asset Held For Sale NoncurrentAssetHeldForSale	5812000
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	516000
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	798000
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	443000
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	487000
CY2024Q2	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	2139000
CY2023Q2	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	8277000
CY2024Q2	us-gaap	Assets Assets	20612000
CY2023Q2	us-gaap	Assets Assets	23268000
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1905000
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1067000
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	955000
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1027000
CY2024Q2	ssy	Current Liabilities Held For Sale CurrentLiabilitiesHeldForSale	0
CY2023Q2	ssy	Current Liabilities Held For Sale CurrentLiabilitiesHeldForSale	1326000
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	331000
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	334000
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1022000
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1115000
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4213000
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4869000
CY2024Q2	ssy	Professional Liability Risks Non Current ProfessionalLiabilityRisksNonCurrent	49000
CY2023Q2	ssy	Professional Liability Risks Non Current ProfessionalLiabilityRisksNonCurrent	138000
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	197000
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	481000
CY2024Q2	ssy	Noncurrent Liabilities Held For Sale NoncurrentLiabilitiesHeldForSale	0
CY2023Q2	ssy	Noncurrent Liabilities Held For Sale NoncurrentLiabilitiesHeldForSale	192000
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	180000
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	171000
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	426000
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	982000
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2024Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	12000000
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	12000000
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7041000
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7041000
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7032000
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7032000
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	3521000
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	3516000
CY2024Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	10747000
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	10746000
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1478000
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3005000
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	227000
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	150000
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15973000
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17417000
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20612000
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23268000
CY2024	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32440000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34280000
CY2024	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	18253000
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	18571000
CY2024	us-gaap	Labor And Related Expense LaborAndRelatedExpense	10561000
CY2023	us-gaap	Labor And Related Expense LaborAndRelatedExpense	10156000
CY2024	us-gaap	Supplies Expense SuppliesExpense	153000
CY2023	us-gaap	Supplies Expense SuppliesExpense	140000
CY2024	ssy	Purchased Services PurchasedServices	1130000
CY2023	ssy	Purchased Services PurchasedServices	1107000
CY2024	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	3014000
CY2023	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	2598000
CY2024	us-gaap	Operating Lease Expense OperatingLeaseExpense	367000
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	372000
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1373000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1262000
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-2411000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	74000
CY2024	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	93000
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	87000
CY2024	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	2000
CY2023	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	30000
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2316000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	191000
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7000
CY2024	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2311000
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	198000
CY2024	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	784000
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1993000
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-1527000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1795000
CY2024	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	77000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	44000
CY2024	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1450000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1751000
CY2024	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.33
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.03
CY2024	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.33
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.03
CY2024	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.11
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.28
CY2024	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.11
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.28
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7038000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7019000
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7038000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7022000
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19120000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1795000
CY2023	ssy	Other Comprehensive Income Loss Minimum Pension Liability Adjustment Net Of Tax OtherComprehensiveIncomeLossMinimumPensionLiabilityAdjustmentNetOfTax	44000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	48000
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17417000
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-1527000
CY2024	ssy	Other Comprehensive Income Loss Minimum Pension Liability Adjustment Net Of Tax OtherComprehensiveIncomeLossMinimumPensionLiabilityAdjustmentNetOfTax	77000
CY2024	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6000
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15973000
CY2024	us-gaap	Profit Loss ProfitLoss	-1527000
CY2023	us-gaap	Profit Loss ProfitLoss	-1795000
CY2024	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1373000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1262000
CY2024	us-gaap	Depreciation And Amortization Discontinued Operations DepreciationAndAmortizationDiscontinuedOperations	322000
CY2023	us-gaap	Depreciation And Amortization Discontinued Operations DepreciationAndAmortizationDiscontinuedOperations	503000
CY2024	ssy	Amortization Of Rou Assets Continuing Operations AmortizationOfRouAssetsContinuingOperations	229000
CY2023	ssy	Amortization Of Rou Assets Continuing Operations AmortizationOfRouAssetsContinuingOperations	299000
CY2024	ssy	Amortization Of Rou Assets Discontinued Operations AmortizationOfRouAssetsDiscontinuedOperations	34000
CY2023	ssy	Amortization Of Rou Assets Discontinued Operations AmortizationOfRouAssetsDiscontinuedOperations	24000
CY2024	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	333000
CY2023	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	733000
CY2024	ssy	Provision For Loss On Receivables Discontinued Operations ProvisionForLossOnReceivablesDiscontinuedOperations	462000
CY2023	ssy	Provision For Loss On Receivables Discontinued Operations ProvisionForLossOnReceivablesDiscontinuedOperations	37000
CY2024	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	2000
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	30000
CY2024	ssy	Impairment Charge For Trace Discontinued Operations ImpairmentChargeForTraceDiscontinuedOperations	1695000
CY2023	ssy	Impairment Charge For Trace Discontinued Operations ImpairmentChargeForTraceDiscontinuedOperations	0
CY2024	ssy	Loss On Sale Of Trace Discontinued Operations LossOnSaleOfTraceDiscontinuedOperations	962000
CY2023	ssy	Loss On Sale Of Trace Discontinued Operations LossOnSaleOfTraceDiscontinuedOperations	0
CY2024	ssy	Gain On Sale Of Trace Extended Care Discontinued Operations GainOnSaleOfTraceExtendedCareDiscontinuedOperations	5584000
CY2023	ssy	Gain On Sale Of Trace Extended Care Discontinued Operations GainOnSaleOfTraceExtendedCareDiscontinuedOperations	0
CY2024	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1112000
CY2023	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	999000
CY2024	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-75000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	20000
CY2024	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	649000
CY2023	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	-1809000
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-158000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-475000
CY2024	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	442000
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-427000
CY2024	ssy	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-340000
CY2023	ssy	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	10000
CY2024	ssy	Increase Decrease In Accrued Sales Taxes IncreaseDecreaseInAccruedSalesTaxes	151000
CY2023	ssy	Increase Decrease In Accrued Sales Taxes IncreaseDecreaseInAccruedSalesTaxes	-2421000
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2978000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-540000
CY2024	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	5000
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	30000
CY2024	ssy	Proceeds From Sale Of Property Plant Equipment Discontinued Operations ProceedsFromSaleOfPropertyPlantEquipmentDiscontinuedOperations	0
CY2023	ssy	Proceeds From Sale Of Property Plant Equipment Discontinued Operations ProceedsFromSaleOfPropertyPlantEquipmentDiscontinuedOperations	194000
CY2024	ssy	Proceeds From Sale Of Trace Discontinued Operations ProceedsFromSaleOfTraceDiscontinuedOperations	500000
CY2023	ssy	Proceeds From Sale Of Trace Discontinued Operations ProceedsFromSaleOfTraceDiscontinuedOperations	0
CY2024	ssy	Proceeds From Sale Of Trace Extended Care Discontinued Operations ProceedsFromSaleOfTraceExtendedCareDiscontinuedOperations	6730000
CY2023	ssy	Proceeds From Sale Of Trace Extended Care Discontinued Operations ProceedsFromSaleOfTraceExtendedCareDiscontinuedOperations	0
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1467000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1341000
CY2024	ssy	Expenditures For Property Plant And Equipment Discontinued Operations ExpendituresForPropertyPlantAndEquipmentDiscontinuedOperations	98000
CY2023	ssy	Expenditures For Property Plant And Equipment Discontinued Operations ExpendituresForPropertyPlantAndEquipmentDiscontinuedOperations	659000
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5670000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1776000
CY2024	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	48000
CY2024	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	14000
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	40000
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-8000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8000
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2684000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2308000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4486000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6794000
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7170000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4486000
CY2024	ssy	Right Of Use Asset Obtained In Exchange For Lease Liability RightOfUseAssetObtainedInExchangeForLeaseLiability	53000
CY2023	ssy	Right Of Use Asset Obtained In Exchange For Lease Liability RightOfUseAssetObtainedInExchangeForLeaseLiability	18000
CY2024	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	104000
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	19000
CY2024	ssy	Interest Paid Received Net InterestPaidReceivedNet	92000
CY2023	ssy	Interest Paid Received Net InterestPaidReceivedNet	120000
CY2024	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. BUSINESS OPERATIONS</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SunLink Health Systems, Inc., through subsidiaries (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”), owns businesses which are providers of healthcare services in certain markets in the United States. SunLink’s business is composed of the ownership of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> businesses, the Pharmacy business and information technology business:</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pharmacy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Pharmacy business is composed of four operational areas:</span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Retail pharmacy products and services provided to residents of southwestern Louisiana;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Institutional pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to institutional clients or to patients in institutional settings, such as nursing homes, assisted living facilities, behavioral and specialty hospitals, hospices, and correctional facilities in Louisiana;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Non-institutional pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to clients or patients in non-institutional settings, including private residences in Louisiana; and,</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DME consisting primarily of the sale and rental of products for institutional clients or to patients in institutional settings and patient-administered home care in Louisiana. </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our other businesses include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A subsidiary, SunLink Health Systems Technology ("SHS Technology”), which provides IT services to outside customers and to SunLink subsidiaries.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A subsidiary which owns and rents to the Trace Real Estate and a subsidiary which owns approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> acres of unimproved land in Houston, Mississippi.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A subsidiary which owned approximately twenty-five (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) acres of unimproved land in Ellijay, Georgia. On September 6, 2024, this land was sold for approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">401</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SunLink subsidiaries have conducted the Pharmacy operations since 2008. Our Pharmacy segment currently is operated through Carmichael’s Cashway Pharmacy, Inc. (“Carmichael”), a subsidiary of our SunLink ScriptsRx, LLC subsidiary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Throughout these notes to the consolidated financial statements, SunLink Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as “SunLink”, “we”, “our”, “ours”, “us” or the “Company.” This drafting style is not meant to indicate that the publicly traded Company or any particular subsidiary of the Company owns or operates any asset, business or property. The operations and businesses described in this filing are owned and operated by distinct and indirect subsidiaries of SunLink Health System, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">COVID-19 Pandemic and CARES Act Funding</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company continued to experience adverse after-effects of the COVID-19 pandemic in the fiscal year ended June 30, 2024 and believes such effects will likely continue to affect its assets and operations in the foreseeable future, particularly salaries and wages pressure, workforce shortages, supply chain disruption and broad inflationary pressures. Our ability to make estimates of any such continuing effects from current or evolving strains of COVID-19 on future revenues, expenses or changes in accounting judgments that have had or are reasonably likely to have a material effect on our financial statements is limited, depending, as they do, on the severity and length thereof; as well as any further government actions and/or regulatory changes intended to address such effects.</span></p>
CY2024	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Management Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> —The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates made by management involve reserves for adjustments to net patient service revenues, evaluation of the recoverability of assets, including receivable-net and intangible assets, and the assessment of litigation and contingencies, including income taxes and related tax asset valuation allowances, all as discussed in more detail in the remainder of these notes to the consolidated financial statements. Actual results could differ materially from these estimates.</span></p>
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> —SunLink’s Pharmacy business subsidiary grants unsecured credit to individual customers and institutional customers. Individual customers primarily are insured under third-party agreements, including Medicare and Medicaid, while the institutional customers are granted credit according to their determined credit risk. Medicare receivables were approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">32</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Pharmacy business’s receivables at June 30, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q2	us-gaap	Cash Cash	7170000
CY2024	ssy	Overnight Repurchase Agreements Collateralized By Government Backed Securities OvernightRepurchaseAgreementsCollateralizedByGovernmentBackedSecurities	1
CY2024Q2	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	1238000
CY2023Q2	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	1191000
CY2024Q2	us-gaap	Workers Compensation Liability Current And Noncurrent WorkersCompensationLiabilityCurrentAndNoncurrent	150
CY2023Q2	us-gaap	Workers Compensation Liability Current And Noncurrent WorkersCompensationLiabilityCurrentAndNoncurrent	150
CY2024	us-gaap	Depreciation Depreciation	1373000
CY2023	us-gaap	Depreciation Depreciation	1262000
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	0
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	0
CY2022Q2	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	127000
CY2023	us-gaap	Financing Receivable Change In Method Credit Loss Expense Reversal FinancingReceivableChangeInMethodCreditLossExpenseReversal	733000
CY2023	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	329000
CY2023Q2	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	531000
CY2024	us-gaap	Financing Receivable Change In Method Credit Loss Expense Reversal FinancingReceivableChangeInMethodCreditLossExpenseReversal	333000
CY2024	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	624000
CY2024Q2	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	240000
CY2024	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32440000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34280000
CY2024	us-gaap	Operating Lease Cost OperatingLeaseCost	340000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	341000
CY2024	ssy	Short Term Lease Cost Income ShortTermLeaseCostIncome	25000
CY2023	ssy	Short Term Lease Cost Income ShortTermLeaseCostIncome	28000
CY2024	ssy	Operating Variable Lease Cost OperatingVariableLeaseCost	2000
CY2023	ssy	Operating Variable Lease Cost OperatingVariableLeaseCost	3000
CY2024	us-gaap	Operating Lease Expense OperatingLeaseExpense	367000
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	372000
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	516000
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	798000
CY2024Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	331000
CY2023Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	334000
CY2024Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	197000
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	481000
CY2024	us-gaap	Operating Lease Payments OperatingLeasePayments	346000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	258000
CY2024	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	53000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	18000
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M12D
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M25D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0123
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0098
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	342000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	175000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	12000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	0
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0
CY2024Q2	ssy	Lessee Operating Lease Liability Payment Due LesseeOperatingLeaseLiabilityPaymentDue	534000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6000
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	528000
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	331000
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	197000
CY2024	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	0
CY2023	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	0
CY2024	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21000
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	380000
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.31
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	195000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.67
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	185000
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.41
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2024	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	9000
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.71
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	176000
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.45
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	185000
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.41
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	176000
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.45
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	176000
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P1Y6M29D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	176000
CY2024	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	9000
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	195000
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	106000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	106000
CY2023	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	44000
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	150000
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	150000
CY2024	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	77000
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	227000
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	227000
CY2024	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	31000
CY2024	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-38000
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7000
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7625000
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8003000
CY2024Q2	ssy	Deferred Tax Assets Depreciation Expense And Impairment Charge DeferredTaxAssetsDepreciationExpenseAndImpairmentCharge	369000
CY2023Q2	ssy	Deferred Tax Assets Depreciation Expense And Impairment Charge DeferredTaxAssetsDepreciationExpenseAndImpairmentCharge	-128000
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	56000
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	295000
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	319000
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	218000
CY2024Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	-275000
CY2023Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	-251000
CY2024Q2	ssy	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	123000
CY2023Q2	ssy	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	233000
CY2024Q2	ssy	Deferred Tax Assets Right Of Use Liabilities DeferredTaxAssetsRightOfUseLiabilities	123000
CY2023Q2	ssy	Deferred Tax Assets Right Of Use Liabilities DeferredTaxAssetsRightOfUseLiabilities	234000
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	124000
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	79000
CY2024Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8218000
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8217000
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8287000
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8286000
CY2024Q2	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	69000
CY2023Q2	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	69000
CY2024	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-520000
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-323000
CY2024	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	344000
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	314000
CY2024	us-gaap	Income Tax Reconciliation Tax Settlements State And Local IncomeTaxReconciliationTaxSettlementsStateAndLocal	181000
CY2023	us-gaap	Income Tax Reconciliation Tax Settlements State And Local IncomeTaxReconciliationTaxSettlementsStateAndLocal	-18000
CY2024	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-10000
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	20000
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7000
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8287000
CY2024Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2024Q2	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	69000
CY2024Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	24458000
CY2024Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	24458000
CY2024	ssy	Net Operating Loss Carry Forwards Expire Period NetOperatingLossCarryForwardsExpirePeriod	2025 through fiscal year 2038
CY2024	ssy	Defined Contribution Plan Employer Matching Contribution DefinedContributionPlanEmployerMatchingContribution	0
CY2023	ssy	Defined Contribution Plan Employer Matching Contribution DefinedContributionPlanEmployerMatchingContribution	0
CY2024	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	0
CY2023	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	0
CY2024Q2	ssy	Plans Assets Invested In Cash And Short Term Investments PlansAssetsInvestedInCashAndShortTermInvestments	0.16
CY2024Q2	ssy	Plans Assets Invested In Equity Investments PlansAssetsInvestedInEquityInvestments	0.67
CY2024Q2	ssy	Plans Assets Invested In Fixed Income Investments PlansAssetsInvestedInFixedIncomeInvestments	0.17
CY2024	ssy	Expected Return On Investment ExpectedReturnOnInvestment	0.04
CY2024Q2	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Next Twelve Months DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths	115
CY2024Q2	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Two DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo	28
CY2024Q2	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Three DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree	37
CY2024Q2	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Four DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour	39
CY2024Q2	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Five DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive	41000
CY2024Q2	ssy	Plan Expected To Pay In Pension Benefits Through Three Years PlanExpectedToPayInPensionBenefitsThroughThreeYears	248000
CY2024	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	20000
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	88000
CY2024	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.051
CY2023	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.045
CY2024	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.04
CY2023	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.04
CY2024	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0
CY2023	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0
CY2023Q2	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	848000
CY2022Q2	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	1172000
CY2024	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	43000
CY2023	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	52000
CY2024	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	27000
CY2023	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	67000
CY2024	us-gaap	Defined Benefit Plan Benefit Obligation Benefits Paid DefinedBenefitPlanBenefitObligationBenefitsPaid	104000
CY2023	us-gaap	Defined Benefit Plan Benefit Obligation Benefits Paid DefinedBenefitPlanBenefitObligationBenefitsPaid	332000
CY2024	us-gaap	Defined Benefit Plan Benefit Obligation Payment For Settlement DefinedBenefitPlanBenefitObligationPaymentForSettlement	1000
CY2023	us-gaap	Defined Benefit Plan Benefit Obligation Payment For Settlement DefinedBenefitPlanBenefitObligationPaymentForSettlement	23000
CY2024Q2	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	761000
CY2023Q2	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	848000
CY2023Q2	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	848000
CY2022Q2	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	1041000
CY2024	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	98000
CY2023	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	51000
CY2024	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	20000
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	88000
CY2024	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	104000
CY2023	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	332000
CY2024Q2	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	862000
CY2023Q2	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	848000
CY2024Q2	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	101000
CY2023Q2	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	0
CY2024	ssy	Unrecognized Actuarial Loss UnrecognizedActuarialLoss	-97000
CY2023	ssy	Unrecognized Actuarial Loss UnrecognizedActuarialLoss	-20000
CY2024Q2	ssy	Accrued Benefit Cost AccruedBenefitCost	4000
CY2023Q2	ssy	Accrued Benefit Cost AccruedBenefitCost	-20000
CY2024Q2	ssy	Defined Benefit Plan Amounts Recognized In Accrued Benefit Cost DefinedBenefitPlanAmountsRecognizedInAccruedBenefitCost	4000
CY2023Q2	ssy	Defined Benefit Plan Amounts Recognized In Accrued Benefit Cost DefinedBenefitPlanAmountsRecognizedInAccruedBenefitCost	-20000
CY2024Q2	ssy	Defined Benefit Plans Accumulated Other Comprehensive Income Minimum Pension Liability Before Tax DefinedBenefitPlansAccumulatedOtherComprehensiveIncomeMinimumPensionLiabilityBeforeTax	-97000
CY2023Q2	ssy	Defined Benefit Plans Accumulated Other Comprehensive Income Minimum Pension Liability Before Tax DefinedBenefitPlansAccumulatedOtherComprehensiveIncomeMinimumPensionLiabilityBeforeTax	-20000
CY2024Q2	us-gaap	Defined Benefit Plan Amounts Recognized In Balance Sheet DefinedBenefitPlanAmountsRecognizedInBalanceSheet	101000
CY2023Q2	us-gaap	Defined Benefit Plan Amounts Recognized In Balance Sheet DefinedBenefitPlanAmountsRecognizedInBalanceSheet	0
CY2024	ssy	Number Of Taxing Authorities NumberOfTaxingAuthorities	2
CY2020Q2	us-gaap	Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority	359000
CY2024	ssy	Sales Tax Receivable SalesTaxReceivable	321000
CY2024	ssy	Sales Tax Settlement SalesTaxSettlement	150000
CY2023Q2	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	2615000
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7038000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7019000
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7038000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7022000
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7038000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7019000
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7038000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7022000
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7038000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7019000
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7038000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7022000
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7038000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7019000
CY2024	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3000
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7038000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7022000
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1000

Files In Submission

Name	View Source	Status
0000950170-24-110311-index-headers.html	Edgar Link	pending
0000950170-24-110311-index.html	Edgar Link	pending
0000950170-24-110311.txt	Edgar Link	pending
0000950170-24-110311-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ssy-20240630.htm	Edgar Link	pending
ssy-20240630.xsd	Edgar Link	pending
ssy-ex21_1.htm	Edgar Link	pending
ssy-ex23_1.htm	Edgar Link	pending
ssy-ex31_1.htm	Edgar Link	pending
ssy-ex31_2.htm	Edgar Link	pending
ssy-ex32_1.htm	Edgar Link	pending
ssy-ex32_2.htm	Edgar Link	pending
ssy-ex97_1.htm	Edgar Link	pending
ssy-20240630_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SSY
SUNLINK HEALTH SYSTEMS INC Stock $ssy

2024 Q3 Form 10-K Financial Statement

#000095017024110311 Filed on September 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSY SUNLINK HEALTH SYSTEMS INC Stock $ssy

2024 Q3 Form 10-K Financial Statement

#000095017024110311 Filed on September 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSY
SUNLINK HEALTH SYSTEMS INC Stock $ssy